Subscribe To
CLLS / Cellectis Announces Participation in Four Upcoming Investor Conferences in September
Content Topics
Cellectis
Announces
Participation
Four
Upcoming
Investor
Conferences
September
Stock
CLLS
CLLS News
By Seeking Alpha
November 3, 2023
Cellectis: End Of 2023 Data Readouts To Boost CAR-T Prospects
Preliminary data from two early-stage studies are going to be shown at the ASH 2023 conference, showcasing its cell therapy candidates for non-Hodgkin more_horizontal
By GlobeNewsWire
November 1, 2023
Cellectis to Report Third Quarter 2023 Financial Results on November 6, 2023
NEW YORK, Nov. 01, 2023 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS- NASDAQ: CLLS), a clinical-stage biotechnology compa more_horizontal
By GlobeNewsWire
September 27, 2023
Cellectis to Present Pre-Clinical Data on Multi-armored Allogeneic MUC1-CAR T-cells Targeting Triple-Negative Breast Cancer at the Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting
NEW YORK, Sept. 27, 2023 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology com more_horizontal
By Seeking Alpha
August 4, 2023
Cellectis SA (CLLS) Q2 2023 Earnings Call Transcript
Cellectis SA (NASDAQ:CLLS ) Q2 2023 Earnings Conference Call August 5, 2023 8:00 AM ET Company Participants Arthur Stril - Chief Business Officer Andr more_horizontal
By Pulse2
February 5, 2023
CLLS Stock: 23.01% Drop Explaination
The stock price of Cellectis SA (NASDAQ: CLLS) fell by 23.01% in the most recent trading session. This is why. more_horizontal
By GlobeNewsWire
December 1, 2022
Cellectis to Host a Live Webcast and Provide a Company Update on December 13, 2022
NEW YORK, Dec. 01, 2022 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology co more_horizontal
By GlobeNewsWire
September 1, 2022
Cellectis Announces Participation in Four Upcoming Investor Conferences in September
NEW YORK, Sept. 01, 2022 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology c more_horizontal
By The Motley Fool
May 20, 2022
Why Cellectis' Shares Rose 22.7% This Week
The company bucked the recent downward trend for biotech companies. more_horizontal